Clinical Trials Directory

Trials / Completed

CompletedNCT00456924

Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914

Prospective Randomized Multicenter Phase II Study of the Dose-Response Effects of Continuous Administration of Low-Dose VA2914 on Parameters of the Hypothalamic-Pituitary-Gonadal Axis and the Endometrium

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
48 (planned)
Sponsor
HRA Pharma · Industry
Sex
Female
Age
18 Years – 35 Years
Healthy volunteers
Accepted

Summary

The purpose of the present study is to evaluate continuous administration of low doses of VA2914 for potential contraceptive activity and effects on the menstrual cycle and steroid hormone parameters.

Conditions

Interventions

TypeNameDescription
DRUGVA2914

Timeline

Start date
2004-01-01
Completion
2004-12-01
First posted
2007-04-05
Last updated
2010-06-17

Locations

4 sites across 2 countries: Belgium, France

Source: ClinicalTrials.gov record NCT00456924. Inclusion in this directory is not an endorsement.

Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914 (NCT00456924) · Clinical Trials Directory